The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed and funded by Alkermes, Inc.
Showing 10 of 99 results
Sort by date:
Ascending
Dec 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
The American Journal of Psychiatry
AUTHOR(S)
Dec 2020
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial
Addictive Behaviors
AUTHOR(S)
Mar 2021
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
Drug Safety
AUTHOR(S)
Mar 2021
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
BMC Psychiatry
AUTHOR(S)
Apr 2021
Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
Clinical Pharmacokinetics
AUTHOR(S)
May 2021
Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
CPT: Pharmacometrics & Systems Pharmacology
AUTHOR(S)
Jun 2021
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
Schizophrenia Research
AUTHOR(S)
Jul 2021
Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil
Psychiatry Research
AUTHOR(S)
Aug 2021
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
CNS Spectrums
AUTHOR(S)
Aug 2021
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Neuropsychiatric Disease and Treatment
AUTHOR(S)
